Silveira, Henrique Spaulonci Cesário, Roberta Carvalho Vígaro, Renan Aparecido Gaiotte, Leticia Barbosa Cucielo, Maira Smaniotto Guimarães, Fernando Seiva, Fábio Rodrigues Ferreira Zuccari, Debora Aparecida P C Reiter, Russel J Chuffa, Luiz Gustavo de Almeida
...
Published in
Molecular and cellular endocrinology
Ovarian cancer (OC) adjusts energy metabolism in favor of its progression and dissemination. Because melatonin (Mel) has antitumor actions, we investigated its impact on energy metabolism and kinase signaling in OC cells (SKOV-3 and CAISMOV-24). Cells were divided into control and Mel-treated groups, in the presence or absence of the antagonist luz...
Floyd, Jessica DeSanto, Kristen Bitler, Benjamin G Brubaker, Lindsay W
Published in
Critical reviews in oncology/hematology
High grade serous carcinoma (HGSC) is the most common and the deadliest histologic subtype of epithelial ovarian cancer. HGSC is a therapeutic challenge, as it recurs in 80 % of patients diagnosed, often as chemoresistant disease. The mechanism of this chemoresistance is not fully elucidated, but it is partly attributed to the ability of HGSC to ma...
Dong, Ming Lu, Lili Xu, Hui Ruan, Zhengyi
Published in
Translational research : the journal of laboratory and clinical medicine
This study investigates the role of dendritic cells (DCs), with a focus on their CXCL10 marker gene, in the activation of cytotoxic T lymphocytes (CTLs) within the ovarian cancer microenvironment and its impact on disease progression. Utilizing scRNA-seq data and immune infiltration analysis, we identified a diminished DC presence in ovarian cancer...
Tang, Rongrong Zhu, Yunshan Chen, Lingfeng Tong, Jinfei Ma, Xudong Sun, Fangying Zheng, Limei Yu, Hailan Yang, Jianhua
Published in
Journal of proteomics
Ovarian cancer is insidious and usually detected in advanced stages of the disease. As the ovaries are pelvic organs, changes in their pelvic fluid metabolites may be associated with ovarian cancer. Metabolomic changes in the pelvic fluid were detected using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in patients with ovarian cancer, ...
Pascual, M.A.; Vancraeynest, L.; Timmerman, S.; 150096; Ceusters, J.; 123496; Ledger, A.; 150837; Graupera, B.; Rodriguez, I.; Valero, B.; Landolfo, C.; Testa, A.C.;
...
OBJECTIVES: To evaluate the ability of the Assessment of Different NEoplasias in the adneXa (ADNEX) model and the International Ovarian Tumour Analysis (IOTA) two-step strategy to predict malignancy in adnexal masses detected in an outpatient low-risk setting, and to estimate the risk of complications in masses with benign ultrasound morphology man...
Evans, D Gareth Morgan, Robert D Crosbie, Emma J Howell, Sacha J Forde, Claire Howell, Anthony Lalloo, Fiona Woodward, Emma R
Published in
Genetics in medicine : official journal of the American College of Medical Genetics
The identification of germline BRCA1/BRCA2 pathogenic variants (PV) infer high remaining lifetime breast/ovarian cancer risks, but there is paucity of studies assessing breast cancer risk after ovarian cancer diagnosis. We reviewed the history of breast cancer in 895 PV heterozygotes (BRCA1 = 541). Cumulative annual breast cancer incidence was asse...
Chase, Dana Shukla, Soham Moore, Julia Boyle, Tirza Lim, Jonathan Perhanidis, Jessica Hurteau, Jean Schilder, Jeanne
INTRODUCTION: Niraparib first-line maintenance (1LM) therapy has demonstrated clinical benefit for patients with ovarian cancer (OC) in clinical trial and real-world settings, but data on factors associated with real-world patient outcomes remain limited. This analysis identified patient characteristics associated with time to next treatment (TTNT)...
Chase, Dana Iadeluca, Laura Lim, Jonathan Tseng, Wan-Yu Bulsara, Purva Patton, Gregory
OBJECTIVE: Previous studies have shown that first-line (1L) maintenance therapy (MT) with poly(ADP-ribose) polymerase inhibitors and/or bevacizumab improves outcomes among patients with advanced ovarian cancer (OC); however, these treatments are underutilized. This study aimed to provide a real-world understanding of MTs among patients with advance...
Szeőcs, Dóra Vida, Beáta Petővári, Gábor Póliska, Szilárd Janka, Eszter Sipos, Adrienn Uray, Karen Sebestyén, Anna Krasznai, Zoárd Bai, Péter
...
Published in
GeroScience
Ascites plays a key role in supporting the metastatic potential of ovarian cancer cells. Shear stress and carry-over of cancer cells by ascites flow support carcinogenesis and metastasis formation. In addition, soluble factors may participate in the procarcinogenic effects of ascites in ovarian cancer. This study aimed to determine the biological e...
Levin, Gabriel Brezinov, Yoav Tzur, Yossi Bar-Noy, Tomer Brodeur, Melica Nourmoussavi Salvador, Shannon Lau, Susie Gotlieb, Walter
Published in
Archives of gynecology and obstetrics
We aimed to study the association between obesity and survival in ovarian cancer (OC) patients, accounting for confounders as disease stage, histology, and comorbidities. Retrospective matched case-control study of consecutive patients, with epithelial OC. Obese (body mass index [BMI] ≥ 35 kg m-2) patients were matched in a 1:4 ratio with patients ...
